Compounds > mibefradil
Page last updated: 2024-08-24

mibefradil and Cardiomyopathies, Primary

mibefradil has been researched along with Cardiomyopathies, Primary in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dumont, L; Jasmin, G; Paquette, F1
Dumont, L; Jasmin, G; Massicotte, J; Villame, J1

Other Studies

2 other study(ies) available for mibefradil and Cardiomyopathies, Primary

ArticleYear
Cardioprotective efficacy of verapamil and mibefradil in young UM-X7.1 cardiomyopathic hamsters.
    Cardiovascular drugs and therapy, 1999, Volume: 13, Issue:6

    Topics: Animals; Biomarkers; Calcinosis; Calcium Channel Blockers; Cardiomyopathies; Cardiovascular Agents; Cricetinae; Female; Heart; Male; Mibefradil; Muscle, Skeletal; Myocardium; Necrosis; Time Factors; Tongue; Verapamil

1999
Effects of mibefradil, a T- and L-type calcium channel blocker, on cardiac remodeling in the UM-X7.1 cardiomyopathic hamster.
    Cardiovascular drugs and therapy, 2001, Volume: 15, Issue:1

    Topics: Animals; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Capillaries; Cardiomyopathies; Cricetinae; Heart Failure; Mesocricetus; Mibefradil; Myocardium; Organ Size; Ventricular Remodeling

2001